Literature DB >> 11546766

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice.

N M Morton1, M C Holmes, C Fiévet, B Staels, A Tailleux, J J Mullins, J R Seckl.   

Abstract

Excess tissue glucocorticoid action may underlie the dyslipidemia, insulin resistance, and impaired glucose tolerance of the metabolic syndrome. 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) catalyzes conversion of circulating inert 11-dehydrocorticosterone into active corticosterone, thus amplifying local intracellular glucocorticoid action, particularly in liver. The importance of 11beta-HSD-1 in glucose homeostasis is suggested by the resistance of 11beta-HSD-1(-/-) mice to hyperglycemia upon stress or obesity, due to attenuated gluconeogenic responses. The present study further investigates the metabolic consequences of 11beta-HSD-1 deficiency, focusing on the lipid and lipoprotein profile. Ad lib fed 11beta-HSD-1(-/-) mice have markedly lower plasma triglyceride levels. This appears to be driven by increased hepatic expression of enzymes of fat catabolism (carnitine palmitoyltransferase-I, acyl-CoA oxidase, and uncoupling protein-2) and their coordinating transcription factor, peroxisome proliferator-activated receptor-alpha (PPARalpha). 11beta-HSD-1(-/-) mice also have increased HDL cholesterol, with elevated liver mRNA and serum levels of apolipoprotein AI. Conversely, liver Aalpha-fibrinogen mRNA levels are decreased. Upon fasting, the normal elevation of peroxisome proliferator-activated receptor-alpha mRNA is lost in 11beta-HSD-1(-/-) mice, consistent with attenuated glucocorticoid induction. Despite this, crucial oxidative responses to fasting are maintained; carnitine palmitoyltransferase-I induction and glucose levels are similar to wild type. Refeeding shows exaggerated induction of genes encoding lipogenic enzymes and a more marked suppression of genes for fat catabolism in 11beta-HSD-1(-/-) mice, implying increased liver insulin sensitivity. Concordant with this, 24-h refed 11beta-HSD-1(-/-) mice have higher triglyceride but lower glucose levels. Further, 11beta-HSD-1(-/-) mice have improved glucose tolerance. These data suggest that 11beta-HSD-1 deficiency produces an improved lipid profile, hepatic insulin sensitization, and a potentially atheroprotective phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546766     DOI: 10.1074/jbc.M103676200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  107 in total

1.  Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles.

Authors:  Scott P Webster; Margaret Binnie; Kirsty M M McConnell; Karen Sooy; Peter Ward; Michael F Greaney; Andy Vinter; T David Pallin; Hazel J Dyke; Matthew I A Gill; Ines Warner; Jonathan R Seckl; Brian R Walker
Journal:  Bioorg Med Chem Lett       Date:  2010-04-18       Impact factor: 2.823

Review 2.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  Robust singular value decomposition analysis of microarray data.

Authors:  Li Liu; Douglas M Hawkins; Sujoy Ghosh; S Stanley Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-27       Impact factor: 11.205

Review 4.  Is "Cushing's disease of the omentum" an affliction of mouse and men?

Authors:  B R Walker
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

5.  On-column ligand exchange for structure-based drug design: a case study with human 11β-hydroxysteroid dehydrogenase type 1.

Authors:  Wenying Qin; Russell A Judge; Kenton L Longenecker; Larry R Solomon; John E Harlan
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-04-21

Review 6.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 7.  11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function.

Authors:  Karen E Chapman; Jonathan R Seckl
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

Review 8.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

Review 9.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

10.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice.

Authors:  Hiroaki Masuzaki; Hiroshi Yamamoto; Christopher J Kenyon; Joel K Elmquist; Nicholas M Morton; Janice M Paterson; Hiroshi Shinyama; Matthew G F Sharp; Stewart Fleming; John J Mullins; Jonathan R Seckl; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.